カテゴリー： Stratistics MRC, 世界, 医療/バイオ

心筋梗塞治療薬の世界市場

【英語タイトル】Myocardial Infarction Therapeutics - Global Market Outlook (2015-2022)

Stratistics MRCが出版した調査資料（SMRC65138）・商品コード：SMRC65138
・発行会社（調査会社）：Stratistics MRC
・発行日：2016年4月
・ページ数：134
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD4,150 ⇒換算￥456,500見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算￥577,500見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算￥825,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
当調査レポートでは、心筋梗塞治療薬の世界市場について調査・分析し、市場動向、市場規模、市場予測、企業動向などを含め、以下の構成でお届けいたします。

・エグゼクティブサマリー
・序文
・市場動向分析
・ファイブフォース分析（市場環境分析）
・心筋梗塞治療薬の世界市場：製品種類別分析/市場規模
・心筋梗塞治療薬の世界市場：流通チャネル別分析/市場規模
・心筋梗塞治療薬の世界市場：地域別分析/市場規模
・心筋梗塞治療薬のアメリカ市場規模予測
・心筋梗塞治療薬のヨーロッパ市場規模予測
・心筋梗塞治療薬のアジア市場規模予測
・企業動向
・企業分析
【レポートの概要】

According to Stratistics MRC, the Myocardial Infarction Therapeutics Market is estimated at $XX million in 2015 and is projected to reach $XX million by 2022 growing at a CAGR of XX% from 2015 to 2022. Growing research application, rising demand in increasing incidence of coronary artery disease and changes in lifestyle are some of the key factors driving the market growth. Increasing number of smokers, increasing incidence of obesity and blood pressures, lack of exercise are some of the factors favouring the market growth. However, saturation in R&D would be the major restraint hampering the market.
Analgesics and antiplatelet agents segments are expected to hold more share in this market as these agents are used for initial treatment of an acute myocardial infarction. North America is the fastest growing market in global myocardial infarction therapeutic market due to rise in aging population and prevalence of co-morbidities.

Some of the key players in the market include Anthera Pharmaceuticals, AstraZeneca, Apotex Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Capricor Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline Plc, Johnson & Johnson, Merck and Co. Inc., Mylan N.V., Novartis N.V., Par Pharmaceutical Companies, Inc., Pfizer Inc., Portola Pharmaceuticals Inc., Sandoz, Sanofi and The Medicines Company.

Products Covered:
• Analgesics
• Antiplatelet agents
• Vasodilators
• Thrombolytics and anti-thrombotic agents
• Glycoprotein IIb/IIIa inhibitors
• Β adrenergic blockers
• Angiotensin receptor antagonists
• Angiotensin converting enzyme inhibitors
• Antithrombotic agents

Distribution Channel Covered:
• Hospitals
• Hospital Pharmacies
• Drug Stores
• Online drug stores

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Myocardial Infarction Therapeutics Market, By Product Type
5.1 Introduction
5.2 Analgesics
5.3 Antiplatelet agents
5.4 Vasodilators
5.5 Thrombolytics and anti-thrombotic agents
5.6 Glycoprotein IIb/IIIa inhibitors
5.7 Β adrenergic blockers
5.8 Angiotensin receptor antagonists
5.9 Angiotensin converting enzyme inhibitors
5.10 Antithrombotic agents

6 Global Myocardial Infarction Therapeutics Market, By Distribution channel
6.1 Introduction
6.2 Hospitals
6.3 Hospital Pharmacies
6.4 Drug Stores
6.5 Online drug stores

7 Global Myocardial Infarction Therapeutics Market, By Geography
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Rest of the World
7.4.1 Middle East
7.4.2 Brazil
7.4.3 Argentina
7.4.4 South Africa
7.4.5 Egypt

8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiling
9.1 Anthera Pharmaceuticals
9.2 AstraZeneca, Apotex Inc.
9.3 Bayer AG
9.4 Boehringer Ingelheim GmbH
9.5 Bristol-Myers Squibb Company
9.6 Capricor Inc.
9.7 Daiichi Sankyo Company Limited
9.8 GlaxoSmithKline Plc
9.9 Johnson & Johnson
9.10 Merck and Co. Inc.
9.11 Mylan N.V.
9.12 Novartis N.V.
9.13 Par Pharmaceutical Companies, Inc.
9.14 Pfizer Inc.
9.15 Portola Pharmaceuticals Inc.
9.16 Sandoz
9.17 Sanofi
9.18 The Medicines Company

List of Tables
Table 1 Global Myocardial Infarction Therapeutics Market Outlook, By Region (2015-2022) ($MN)
Table 2 Global Myocardial Infarction Therapeutics Market Outlook, By Product (2015-2022) ($MN)
Table 3 Global Myocardial Infarction Therapeutics Market Outlook, By Analgesics (2015-2022) ($MN)
Table 4 Global Myocardial Infarction Therapeutics Market Outlook, By Antiplatelet agents (2015-2022) ($MN)
Table 5 Global Myocardial Infarction Therapeutics Market Outlook, By Vasodilators (2015-2022) ($MN)
Table 6 Global Myocardial Infarction Therapeutics Market Outlook, By Thrombolytics and anti-thrombotic agents (2015-2022) ($MN)
Table 7 Global Myocardial Infarction Therapeutics Market Outlook, By Glycoprotein IIb/IIIa inhibitors (2015-2022) ($MN)
Table 8 Global Myocardial Infarction Therapeutics Market Outlook, By Β adrenergic blockers (2015-2022) ($MN)
Table 9 Global Myocardial Infarction Therapeutics Market Outlook, By Angiotensin receptor antagonists (2015-2022) ($MN)
Table 10 Global Myocardial Infarction Therapeutics Market Outlook, By Antithrombotic agents (2015-2022) ($MN)
Table 11 Global Myocardial Infarction Therapeutics Market Outlook, By Distribution channel (2015-2022) ($MN)
Table 12 Global Myocardial Infarction Therapeutics Market Outlook, By Hospitals (2015-2022) ($MN)
Table 13 Global Myocardial Infarction Therapeutics Market Outlook, By Hospital Pharmacies (2015-2022) ($MN)
Table 14 Global Myocardial Infarction Therapeutics Market Outlook, By Drug Stores (2015-2022) ($MN)
Table 15 Global Myocardial Infarction Therapeutics Market Outlook, By Online drug stores (2015-2022) ($MN)
Table 16 North America Myocardial Infarction Therapeutics Market Outlook, By Product (2015-2022) ($MN)
Table 17 North America Myocardial Infarction Therapeutics Market Outlook, By Analgesics (2015-2022) ($MN)
Table 18 North America Myocardial Infarction Therapeutics Market Outlook, By Antiplatelet agents (2015-2022) ($MN)
Table 19 North America Myocardial Infarction Therapeutics Market Outlook, By Vasodilators (2015-2022) ($MN)
Table 20 North America Myocardial Infarction Therapeutics Market Outlook, By Thrombolytics and anti-thrombotic agents (2015-2022) ($MN)
Table 21 North America Myocardial Infarction Therapeutics Market Outlook, By Glycoprotein IIb/IIIa inhibitors (2015-2022) ($MN)
Table 22 North America Myocardial Infarction Therapeutics Market Outlook, By Β adrenergic blockers (2015-2022) ($MN)
Table 23 North America Myocardial Infarction Therapeutics Market Outlook, By Angiotensin receptor antagonists (2015-2022) ($MN)
Table 24 North America Myocardial Infarction Therapeutics Market Outlook, By Antithrombotic agents (2015-2022) ($MN)
Table 25 North America Myocardial Infarction Therapeutics Market Outlook, By Distribution channel (2015-2022) ($MN)
Table 26 North America Myocardial Infarction Therapeutics Market Outlook, By Hospitals (2015-2022) ($MN)
Table 27 North America Myocardial Infarction Therapeutics Market Outlook, By Hospital Pharmacies (2015-2022) ($MN)
Table 28 North America Myocardial Infarction Therapeutics Market Outlook, By Drug Stores (2015-2022) ($MN)
Table 29 North America Myocardial Infarction Therapeutics Market Outlook, By Online drug stores (2015-2022) ($MN)
Table 30 Europe Myocardial Infarction Therapeutics Market Outlook, By Product (2015-2022) ($MN)
Table 31 Europe Myocardial Infarction Therapeutics Market Outlook, By Analgesics (2015-2022) ($MN)
Table 32 Europe Myocardial Infarction Therapeutics Market Outlook, By Antiplatelet agents (2015-2022) ($MN)
Table 33 Europe Myocardial Infarction Therapeutics Market Outlook, By Vasodilators (2015-2022) ($MN)
Table 34 Europe Myocardial Infarction Therapeutics Market Outlook, By Thrombolytics and anti-thrombotic agents (2015-2022) ($MN)
Table 35 Europe Myocardial Infarction Therapeutics Market Outlook, By Glycoprotein IIb/IIIa inhibitors (2015-2022) ($MN)
Table 36 Europe Myocardial Infarction Therapeutics Market Outlook, By Β adrenergic blockers (2015-2022) ($MN)
Table 37 Europe Myocardial Infarction Therapeutics Market Outlook, By Angiotensin receptor antagonists (2015-2022) ($MN)
Table 38 Europe Myocardial Infarction Therapeutics Market Outlook, By Antithrombotic agents (2015-2022) ($MN)
Table 39 Europe Myocardial Infarction Therapeutics Market Outlook, By Distribution channel (2015-2022) ($MN)
Table 40 Europe Myocardial Infarction Therapeutics Market Outlook, By Hospitals (2015-2022) ($MN)
Table 41 Europe Myocardial Infarction Therapeutics Market Outlook, By Hospital Pharmacies (2015-2022) ($MN)
Table 42 Europe Myocardial Infarction Therapeutics Market Outlook, By Drug Stores (2015-2022) ($MN)
Table 43 Europe Myocardial Infarction Therapeutics Market Outlook, By Online drug stores (2015-2022) ($MN)
Table 44 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Product (2015-2022) ($MN)
Table 45 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Analgesics (2015-2022) ($MN)
Table 46 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Antiplatelet agents (2015-2022) ($MN)
Table 47 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Vasodilators (2015-2022) ($MN)
Table 48 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Thrombolytics and anti-thrombotic agents (2015-2022) ($MN)
Table 49 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Glycoprotein IIb/IIIa inhibitors (2015-2022) ($MN)
Table 50 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Β adrenergic blockers (2015-2022) ($MN)
Table 51 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Angiotensin receptor antagonists (2015-2022) ($MN)
Table 52 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Antithrombotic agents (2015-2022) ($MN)
Table 53 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Distribution channel (2015-2022) ($MN)
Table 54 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Hospitals (2015-2022) ($MN)
Table 55 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Hospital Pharmacies (2015-2022) ($MN)
Table 56 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Drug Stores (2015-2022) ($MN)
Table 57 Asia pacific Myocardial Infarction Therapeutics Market Outlook, By Online drug stores (2015-2022) ($MN)
Table 58 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Product (2015-2022) ($MN)
Table 59 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Analgesics (2015-2022) ($MN)
Table 60 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Antiplatelet agents (2015-2022) ($MN)
Table 61 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Vasodilators (2015-2022) ($MN)
Table 62 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Thrombolytics and anti-thrombotic agents (2015-2022) ($MN)
Table 63 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Glycoprotein IIb/IIIa inhibitors (2015-2022) ($MN)
Table 64 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Β adrenergic blockers (2015-2022) ($MN)
Table 65 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Angiotensin receptor antagonists (2015-2022) ($MN)
Table 66 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Antithrombotic agents (2015-2022) ($MN)
Table 67 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Distribution channel (2015-2022) ($MN)
Table 68 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Hospitals (2015-2022) ($MN)
Table 69 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Hospital Pharmacies (2015-2022) ($MN)
Table 70 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Drug Stores (2015-2022) ($MN)
Table 71 Rest of the World Myocardial Infarction Therapeutics Market Outlook, By Online drug stores (2015-2022) ($MN)



【レポートのキーワード】

心筋梗塞、心筋梗塞治療薬

★調査レポート[心筋梗塞治療薬の世界市場] (コード：SMRC65138)販売に関する免責事項を必ずご確認ください。
★調査レポート[心筋梗塞治療薬の世界市場]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 抗血栓薬の世界市場
    SMRC70523031 / Stratistics MRC / 2017年2月 / 当調査レポートでは、抗血栓薬の世界市場について調査・分析し、抗血栓薬の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。 - エグゼクティブサマリー - 序文 - 抗血栓薬の世界市場：市場動向分析 - 抗血栓薬の世界市場：競争要因分析 -...According to Stratistics MRC, the Global Antithrombotic Drugs market is accounted for $XX million in 2016 and is expected to reach $XX million by 2022 growing at a CAGR of XX% from 2016 to 2022. Rising prevalence of chronic diseases associated with thrombotic disease require long-term administration of antithrombotic drugs, which is the key factor enhancing the demand for antithrombotic drugs market. Furthermore, growing geriatric population, increasing hereditary diseases, lack of physical activity, increasing awareness among patients about life-threatening diseases, changing lifestyles and increasing hypertension are the factors favouring market growth. However, off- patented drugs, postoperative bleeding and availability of...

    • ◆H&Iグローバルリサーチのお客様（例）◆